Objective: To investigate the pharmacokinetic properties of hyperoside in beagle dog plasma. Method: The analysis was carried out on a Diamonsil C18 (2) reversed-phase column (4.6 mm×250 mm

5 mm) by isocratic elution with acetonitrile and 0.1% phosphoric acid (42: 58). The flow rate was 1.0 mL· min-1 and the detection wavelength was set at 360 nm. Beagle dogs were oral administrated

and at different time points

the concentrations of hyperoside in dog plasma were determined by HPLC method. Main pharmacokinetics parameters were estimated by non-compartmental analysis using the Kinetica 4.4 software. Result: Linear response was obtained for hyperoside ranging from 0.5 to 100 mg· L-1. The intra-and inter-day precisions (RSDs) were less than 5.9%. The extraction recovery ranged from 89.95% to 95.32%. Stability studies showed that hyperoside was stable in preparation and analytical process. Hyperoside plasma concentration reached a maximum at(2.17±0.41)h after administration with an average Cmax of (13.88±1.26) mg· L-1. The area under the curve (AUC0-∞) was (96.69±30.94 )μg· h-1· mL-1. The MRT was (8.28±3.79) h. Conclusion: The results indicated that the validated method was successfully used to determine the concentration-time profiles of hyperoside.